Therapeutic options: An evidence-based approach to prevention and treatment of osteoporosis

International Journal of Fertility and Women's Medicine

Volumn 48, Issue 3, 2003, Pages 122-126

  Miller, Ellen ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Hormone therapy; HRT; HT; Osteoporosis; Prevention; Treatment; WHI; Women's Health Initiative

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

ALENDRONATE; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ETIDRONIC ACID; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE;

EID: 0038796592     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Writing group for Women's Health Initiative. JAMA 288:321-333, 2002.
2. Tremollieres FA, Pouilles J-M, Ribot C: Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporosis Int 12:385-390, 2001.
3. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999.
4. Chestnut et al: Am J Med 109:267-276, 2000.
5. Ascot-Evans BH et al: Arch Intern Med 163:789-794, 2003.
6. Black DM, Cummings SR, Karpf DB, et al: Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996.
7. Merck & Co., DA-FOS73(1).
8. Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082, 1998.
9. Harris ST, Watts NB, Genant HK, et al: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352, 1999.
10. Reginster J, Minne HW, Sorensen OH, et al: Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 11:83-91, 2000.
11. McClung M, Geusens P, Miller P, et al: Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 344:333-340, 2001.